AI Engines For more Details: Perplexity Kagi Labs You
Antidepressant Effects: Iproniazide phosphate was primarily used for its antidepressant properties. As an MAOI, it works by inhibiting the activity of the enzyme monoamine oxidase, which is involved in the breakdown of neurotransmitters such as serotonin, dopamine, and norepinephrine. By inhibiting monoamine oxidase, iproniazide phosphate increases the levels of these neurotransmitters in the brain, which can help alleviate symptoms of depression.
Side Effects: Like other MAOIs, iproniazide phosphate is associated with a range of side effects, some of which can be serious. Common side effects may include drowsiness, dizziness, blurred vision, dry mouth, constipation, urinary retention, and sexual dysfunction. These side effects may diminish over time as the body adjusts to the medication, but they can be bothersome for some individuals.
Hypertensive Crisis: One of the most significant risks associated with iproniazide phosphate and other MAOIs is the potential for a hypertensive crisis, also known as a hypertensive reaction. This occurs when the medication interacts with certain foods or drugs that contain tyramine or other sympathomimetic agents, leading to a sudden and dangerous increase in blood pressure. Symptoms of a hypertensive crisis may include severe headache, palpitations, chest pain, nausea, vomiting, sweating, and shortness of breath. If left untreated, a hypertensive crisis can lead to stroke, heart attack, or organ damage.
Drug Interactions: Iproniazide phosphate can interact with a wide range of medications, including other antidepressants, sympathomimetic agents, stimulants, cold and allergy medications, and certain foods and beverages (such as aged cheeses, cured meats, and alcoholic beverages). These interactions can increase the risk of serotonin syndrome, hypertensive crisis, or other adverse effects. Therefore, it is important for individuals taking iproniazide phosphate to carefully avoid these interactions and consult with their healthcare provider before starting or stopping any medications.
Liver Toxicity: Rarely, iproniazide phosphate may cause liver toxicity or liver damage. Signs of liver toxicity may include jaundice (yellowing of the skin or eyes), dark urine, abdominal pain, and unusual fatigue. Individuals taking iproniazide phosphate should be monitored regularly for signs of liver dysfunction, and treatment should be discontinued if liver toxicity is suspected.
Withdrawal Syndrome: Abrupt discontinuation of iproniazide phosphate or other MAOIs may lead to a withdrawal syndrome characterized by flu-like symptoms, anxiety, agitation, and mood changes. Therefore, it is important to gradually taper off the medication under the supervision of a healthcare professional to minimize the risk of withdrawal symptoms.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.1 | 0.1 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.4 | 0.4 | |
| Allergies | 0.7 | 0.1 | 6 |
| Allergy to milk products | 0.8 | 0.4 | 1 |
| Alzheimer's disease | 0.6 | 0.1 | 5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.8 | -1 |
| Ankylosing spondylitis | 1.1 | 0.1 | 10 |
| Anorexia Nervosa | 0.1 | -0.1 | |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Atherosclerosis | 0.1 | 0.1 | |
| Atrial fibrillation | 0.1 | 0.4 | -3 |
| Autism | 0.5 | 0.5 | 0 |
| Barrett esophagus cancer | 0.1 | 0.1 | |
| benign prostatic hyperplasia | 0.4 | 0.4 | |
| Bipolar Disorder | 0.4 | 0.1 | 3 |
| Carcinoma | 0.4 | 0.1 | 3 |
| Celiac Disease | 0.7 | 0.1 | 6 |
| Cerebral Palsy | 0.1 | -0.1 | |
| Chronic Fatigue Syndrome | 0.2 | 0.2 | 0 |
| Chronic Kidney Disease | 0.4 | 0.1 | 3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.1 | 0 |
| Chronic Urticaria (Hives) | 1.1 | 1.1 | |
| Coagulation / Micro clot triggering bacteria | 1.1 | 0.1 | 10 |
| Colorectal Cancer | 1.4 | 1.4 | |
| Constipation | 0.4 | 0.4 | |
| Coronary artery disease | 0.1 | 0.1 | 0 |
| COVID-19 | 1.2 | 0.2 | 5 |
| Crohn's Disease | 1.4 | 0.2 | 6 |
| cystic fibrosis | 1.1 | 1.1 | |
| deep vein thrombosis | 1.1 | 0.1 | 10 |
| Depression | 0.8 | 0.6 | 0.33 |
| Eczema | 0.4 | 0.4 | |
| Endometriosis | 1.2 | 0.1 | 11 |
| Eosinophilic Esophagitis | 0.1 | 0.1 | |
| Epilepsy | 0.4 | 0.4 | |
| Fibromyalgia | 0.1 | -0.1 | |
| Functional constipation / chronic idiopathic constipation | 1.1 | 0.1 | 10 |
| gallstone disease (gsd) | 0.4 | 0.1 | 3 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.1 | |
| Generalized anxiety disorder | 1.2 | 0.1 | 11 |
| Gout | 0.1 | -0.1 | |
| Halitosis | 0.1 | 0.1 | |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.7 | 0.7 | |
| hyperglycemia | 0.4 | 0.4 | |
| hypertension (High Blood Pressure | 0.4 | 0.1 | 3 |
| Hypothyroidism | 0.1 | -0.1 | |
| Inflammatory Bowel Disease | 1.1 | 0.2 | 4.5 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 1.1 | 1.1 | |
| Liver Cirrhosis | 0.5 | 0.1 | 4 |
| Long COVID | 0.6 | 0.3 | 1 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.4 | 0.1 | 3 |
| ME/CFS with IBS | 0.1 | -0.1 | |
| ME/CFS without IBS | 0.1 | 0.1 | |
| Metabolic Syndrome | 1.3 | 0.2 | 5.5 |
| Mood Disorders | 0.9 | 0.6 | 0.5 |
| Multiple Sclerosis | 0.1 | 0.1 | 0 |
| Multiple system atrophy (MSA) | 0.1 | -0.1 | |
| Neuropathy (all types) | 0.4 | -0.4 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.1 | 3 |
| Obesity | 0.5 | 0.2 | 1.5 |
| obsessive-compulsive disorder | 1.2 | 0.1 | 11 |
| Osteoarthritis | 0.4 | 0.1 | 3 |
| Osteoporosis | 0.4 | 0.4 | |
| Parkinson's Disease | 0.8 | 0.5 | 0.6 |
| Polycystic ovary syndrome | 0.4 | 0.1 | 3 |
| Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
| Psoriasis | 0.8 | 0.1 | 7 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.1 | 5 |
| Rosacea | 0.1 | 0.1 | |
| Schizophrenia | 0.1 | 0.1 | 0 |
| scoliosis | 0.1 | 0.1 | 0 |
| Sjögren syndrome | 0.4 | 0.4 | |
| Sleep Apnea | 0.2 | 0.1 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.1 | 7 |
| Systemic Lupus Erythematosus | 0.5 | 0.1 | 4 |
| Tic Disorder | 0.1 | 0.1 | |
| Type 1 Diabetes | 0.5 | 0.5 | |
| Type 2 Diabetes | 1.3 | 0.9 | 0.44 |
| Ulcerative colitis | 1.1 | 0.1 | 10 |
| Unhealthy Ageing | 0.3 | 0.1 | 2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.